Impact of inhaled corticosteroid-induced oropharyngeal adverse events: Results from a meta-analysis

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 3, 2007, Pages 225-238

  Rachelefsky, Gary S ^a,d   Liao, Yuning ^b   Faruqi, Rab ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANOFI   (France)

^c Allergy Research Foundation Inc ^*

^d Allergy Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; MONTELUKAST; PLACEBO; SALMETEROL; TRIAMCINOLONE ACETONIDE;

ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRY POWDER; DYSPHONIA; HUMAN; LOW DRUG DOSE; LUNG FUNCTION TEST; MEDLINE; META ANALYSIS; METERED DOSE INHALER; MOUTH HYGIENE; OROPHARYNX; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE BLIND PROCEDURE; SYSTEMATIC REVIEW; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33947251723     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60711-9     Document Type: Article

References (65)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2004. Available at: www.ginasthma. org. Accessed June 2006.
2. National Institutes of Health. National Asthma Education and Prevention Programme. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997. Publication 1997;97-4051.
3. National Institutes of Health, National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Programme Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics 2002. J Allergy Clin Immunol. 2002;110:S142-S219.
4. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332-336.
5. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med. 1998;157(3 pt 2):S1-S53.
6. Banov C, Howland WC III, Lumry WR, et al. Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma. Allergy Asthma Proc. 2003;24:129-136.
7. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-1063.
8. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;145:669-674.
9. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy, a systematic review and meta-analysis. Arch Intern Med. 1999;159:941-955.
10. Dubus JC, Marguet C, Deschildre A, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56:944-948.
11. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45:146-152.
12. Toogood JH, Jennings B, Greenway RW, Chuang L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol. 1980;65:145-153.
13. Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax. 1983;38:813-821.
14. Selroos O, Backman R, Forsen KO, et al. Local side-effects during 4-year treatment with inhaled corticosteroids-a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy. 1994;49:888-890.
15. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J. 1995;8:590-592.
16. Kennedy WA, Laurier C, Gautrin D, et al. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. J Clin Epidemiol. 2000;53: 696-701.
17. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91(suppl A):22-28.
18. Jackson LD, Polygenis D, McIvor RA, Worthington I. Comparative efficacy and safety of inhaled corticosteroids in asthma. Can J Clin Phamacol. 1999;6:26-37.
19. Toogood JH. Complications of topical steroid therapy for asthma. Am Rev Respir Dis. 1990;141(2 pt 2):S89-S96.
20. Knight L, Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J Infect Dis. 1971;123: 371-377.
21. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98:196-208.
22. Milne LJ, Crompton GK. Beclomethasone dipropionate and oropharyngeal candidiasis. BMJ. 1974;3:797-798.
23. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213-219.
24. Hyland ME. Rationale for once-daily therapy in asthma: compliance issues. Drugs. 1999;58(suppl 4):1-6; discussion 51.
25. Szefler SJ, Leung DYM, Severe asthma: pathogenesis and clinical management. In: Rand CS, Wise RA, eds. Adherence With Asthma Therapy in the Management of Asthma. New York, NY: Marcel Dekker; 1996:435-464.
26. Schmier JK, Chan KS, Leidy NK. The impact of asthma on health-related quality of life. J Asthma. 1998;35:585-597.
27. Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma. 1998;35:455-472.
28. Rachelefsky G. Inhaled corticosteroids and the risk of oropharyngeal adverse events: results from a meta-analysis. J Allergy Asthma Immunol. 2006;117:S92 (abstract 358).
29. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention Revised: National Heart, Lung, and Blood Institute/WHO Workshop Report. Bethesda, MD: National Institutes of Health; 2002. Publication 02-3659.
30. Cochrane handbook for systematic reviews of interventions 4.2.4. In: Higgins JPT, Green P, eds. The Cochrane Library. Chichester, England: John Wiley & Sons Ltd: 2005:2.
31. Chervinsky P, Nelson HS, Bernstein DI, Berkowitz RA, Siegel SC. Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. Int J Clin Pract. 2002;56:419-425.
32. Corren J, Berkowitz R, Murray JJ, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract. 2003;57:567-572.
33. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999;160:1862-1868.
34. Bronsky E, Korenblat P, Harris AG, Chen R. Comparative clinical study of inhaled beclomethasone dipropionate and triamcinolone acetonide in persistent asthma. Ann Allergy Asthma Immunol. 1998;80:295-302.
35. Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol. 2000;84: 417-424.
36. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med. 1999;93:603-612.
37. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000;105(6 pt 1): 1108-1116.
38. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000;161 (2 pt 1):527-534.
39. Pearlman DS, Noonan MJ, Tashkin DP, et al. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Ann Allergy Asthma Immunol. 1997;78:356-362.
40. Nathan RA, Li JT, Finn A, et al. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest. 2000; 118:296-302.
41. Condemi JJ, Chervinsky P, Goldstein MF, et al. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. J Allergy Clin Immunol. 1997;100:467-474.
42. Nelson HS, Busse WW, deBoisblanc BP, et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol. 1999;103(2 pt 1): 267-275.
43. Galant SP, van Bavel J, Finn A, et al. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 1999;82:273-280.
44. Chervinsky P, As Av, Bronsky E, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol. 1994;94:676-683.
45. Wolfe JD, Seiner JC, Mendelson LM, Hampel F Jr, Schaberg A. Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin Ther. 1996;18: 635-646.
46. Welch M, Bernstein D, Gross G, Kane RE, Banerji D; Azmacort HFA Study Group. A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Chest. 1999;116: 1304-1312.
47. Kemp J, Wanderer AA, Ramsdell J, et al. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol. 1999;82: 463-471.
48. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998;101(4 pt 1): 457-463.
49. Metzger WJ, Hempel FC, Sugar M. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) is effective and safe in adults previously treated with inhaled corticosteroids. J Asthma. 2002;39:65-75.
50. Boe J, Rosenhall L, Alton M, et al. Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. Allergy. 1989;44: 349-355.
51. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane- 134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest. 1999;115:343-351.
52. Nathan RA, Nolop KB, Cuss FM, Lorber RR. A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma. Chest. 1997;112:34-39.
53. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol. 2000;106: 852-860.
54. Vogt FC. The incidence of oral candidiasis with use of inhaled corticosteroids. Ann Allergy. 1979;43:205-210.
55. Harrison LI, Soria I, Cline AC, Ekholm BP. Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol. 1999;51: 1235-1240.
56. Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996;51:977-980.
57. Harrison LI. Local versus total systemic bioavailability of beclomethasone dipropionate CFC and HFA metered dose inhaler formulations. J Aerosol Med. 2002;15:401-406.
58. Kelloway JS, Wyatt NN, Adlis S, Schoenwetter WF. Does using a mouthwash instead of water improve the oropharyngeal removal of inhaled Flovent (fluticasone propionate). Allergy Asthma Proc. 2001;22:367-371.
59. Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther. 1993;58:173-209.
60. Yokoyama H, Nakajima Y, Yamamura Y, et al. Investigation of mouth washing by patients after inhaling corticosteroids. Yakugaku Zasshi. 2005;125:455-461.
61. Zanon P. Inhalation anti-asthma therapy with spacers: technical aspects. Monaldi Arch Chest Dis. 1994;49:258-264.
62. Toogood JH, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1984;129:723-729.
63. Dickens GR, Wermeling DP, Matheny CJ, et al. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol. 2000;84:528-532.
64. Toogood JH, Jennings B, Baskerville J, et al. Dosing regimen of budesonide and occurrence of oropharyngeal complications. Eur J Respir Dis. 1984;65:35-44.
65. Kaliner M, Crivera C, Szcwarcberg J, et al. Physician responses to oropharyngeal adverse events caused by inhaled corticosteroids in adults with asthma. J Allergy Clin Immunol. 2005;115:S209.